August 2016

Proprietary T-cell Redirecting Bispecific CD33/CD3 Antibody for the Treatment of AML Nears First-in-Human Study  SAN FRANCISCO, CA, August 10, 2016 --- Amphivena Therapeutics, Inc., a developer of cancer immunotherapies, announced today that the U.S. Food and Drug Administration (FDA) has accepted an investigational new drug (IND)...